ReviewNeuron2023
Cognitive heterogeneity in Parkinson's disease: A mechanistic view.
Review in Neuron, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Mapping the research landscape of Mild Cognitive Impairment in Parkinson's disease: a bibliometric and visualization analysis.Frontiers in aging neuroscience · 2025Pooled it
- A task-aligned multimodal machine learning framework for studying working memory dysfunction in Parkinson's disease.Cognitive neurodynamics · 2026Article
- Article
- A nomogram combined substantia nigra hyperechogenicity with third ventricular width assessed by transcranial sonography in prediction Parkinson's disease-related cognitive impairment.BMC medical imaging · 2026Article
- Hippocampal atrophy in untreated de novo Parkinson's disease with obstructive sleep apnea.NPJ Parkinson's disease · 2026Article
- Altered cerebrovascular haemodynamics in Parkinson's disease: Insights from 4D flow MRI.NPJ Parkinson's disease · 2026Article
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Article
- Association Between Pain Subtypes and Cognitive Impairment in Parkinson's Disease.Journal of pain research · 2026Article
- A neuroimmune-enriched multibiofluid proteomic index associated with cognitive-motor progression in early Parkinson's disease: a longitudinal PPMI cohort study.Frontiers in immunology · 2026Article
- Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.Brain sciences · 2025Review
- APOE4 promotes nigral tau hyperphosphorylation through cholesterol in atherosclerosis.Cell death discovery · 2025Article
- Review of the Effects of Lifestyle Modification on Parkinson's Disease.American journal of lifestyle medicine · 2025Article
- Cortical volumetry and longitudinal cognitive changes in Parkinson's disease: insights from the COPPADIS cohort.Brain imaging and behavior · 2025Article
- Intercellular propagation of RIPK1/RIPK3 amyloid fibrils.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Tackling a disease on a global scale, the Global Parkinson's Genetics Program, GP2: A new generation of opportunities.American journal of human genetics · 2025Review
- Triglyceride-glucose index predicts cognitive decline and striatal dopamine deficiency in Parkinson disease in two cohorts.NPJ Parkinson's disease · 2025Article
- A predictive model for longitudinal cognitive subtypes in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Calcium modulating ligand confers risk for Parkinson's disease and impacts lysosomes.Annals of clinical and translational neurology · 2025Article
- Association between third ventricular width assessed by transcranial sonography and plasma homocysteine in Parkinson's disease with cognitive impairment and their potential to predict conversion to dementia.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cognitive impairment occurs in most individuals with Parkinson's disease (PD), exacting a high toll on patients, their caregivers, and the healthcare system. In this review, we begin by summarizing the current clinical landscape surrounding cognition in PD. We then discuss how cognitive impairment and dementia may develop in PD based on the spread of the pathological protein alpha-synuclein (aSyn) from neurons in brainstem regions to those in the cortical regions of the brain responsible for higher cognitive functions, as first proposed in the Braak hypothesis. We appraise the Braak hypothesis from molecular (conformations of aSyn), cell biological (cell-to-cell spread of pathological aSyn), and organ-level (region-to-region spread of aSyn pathology at the whole brain level) viewpoints. Finally, we argue that individual host factors may be the most poorly understood aspect of this pathological process, accounting for substantial heterogeneity in the pattern and pace of cognitive decline in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.